CD56、TPO、p63及CK19联合检测与甲状腺乳头状癌临床病理的相关性

Abstract
Figure/Table
References (0)
Related Citation (5)

Download: PDF (797 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To explore the correlation between combined detection of CD56, TPO, p63 and CK19 and clinicopathologic parameter in papillary thyroid carcinoma. Methods: one hundred patients with PTC were detected by immunohistochemistry for the expression of the CD56, TPO, p63 and CK19, and the Chi-square test was utilized to statistical analyze the relation between the above markers and clinicopathologic parameter (gender, age, number, size, location, capsule invasion, lymph node metastasis, histologic subtype of lesion). Results: The expression positive rate of CD56, TPO, p63 and CK19 was 11%, 5%, 17%, 87% respectively in 100 cases of PTC. No correlation between four markers and the clinicopathologic parameters (gender, age, number, size, location, lymph node metastasis, histologic subtype of lesion), there was no statistically significant difference (P>0.05), but the expression of CD56 in cases with capsule invasion was significantly lower than without capsule invasion, the difference was statistically significant (P<0.05), there was no correlation between expression of the other three markers and capsule invasion, the difference was not statistically significant (P>0.05). Conclusion: There is correlation between the expression of CD56 and capsule invasion, the expression of CD56 in cases with capsule invasion was significantly lower than without capsule invasion, and the low expression can predict the poor prognosis in PTC.

Key words： papillary thyroid carcinoma CD56 TPO p63 CK19 clinicopathologic correlation

Received: 14 March 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiufang
	LV Yanting
	ZHANG Haiyong
	ZHAO Feixing
	HU Mengjun.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I3/205

[1] 胡孟钧, 吕艳婷, 郦秀芳, 等. CK19、TPO、CD56及p63标记在甲状腺良恶性乳头状增生诊断与鉴别诊断中价值[J].临床与实验病理学杂志, 2011, 27(5): 544-546.

[2] EI Demellawy D, Nasr A, Alowami S. Application of CD56,p63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid[J]. Diagn Pathol, 2008,3: 5.

[3] Haas S, G gemann I, Wolff M, et al. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma[J]. Am J Surg Pathol, 2007,31(6): 902-906.

[4] 黄悦, 黄文斌, 赵建华, 等. CD56在甲状腺乳头状癌诊断中的价值[J]. 诊断病理学杂志, 2010, 117(1): 14-16.

[5] Scarpino S, Di Napoli A, Mellotti F, et al. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells[J]. J Pathol, 2007, 212(4): 411-419.

[6] 周庚寅, 刘洪琪, 张庆慧. 肿瘤组织病理诊断[M]. 济南: 山东科技出版社, 2001: 604-605.

[7] 柯昌庶. 甲状腺包膜型乳头状癌滤泡亚型的诊断[J]. 临床与实验病理学杂志, 2004, 20(2): 245-246.

[8] 程文元, 徐本义, 张仑. 甲状腺乳头状癌致死因素分析 (附749例病例报告) [J]. 天津医科大学学报, 2002, 8(1): 83-84.

[9] Savin S, Cvejic D, Isic T, et al. Thyroid peroxidase immuno-histochemistry in differential diagnosis of thyroid tumors [J]. Endocr Pathol, 2006, 17(1): 53-60.

[10] 胡孟钧, 郦秀芳, 魏建丽, 等. 甲状腺肿瘤COX-2CK19TPO表达及其意义[J]. 临床与实验病理学杂志, 2006, 22(2): 240-241.

[11] Isic Dencic T, Cvejic D, Paunovic I, et al. Cytokeratin 19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior[J].Med Oncol, 2013, 30(1): 362.

[12] Pellegrini G, Dellambra E, Golisano, et al. P63 identifies keratinocyte stem cells[J]. Proc Natl Acad Sci USA, 2001,98(6): 3156-3161.

[13] Burstein DE, Nagi C, Wang BY. Immunohistochemical de-tection of P53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's thyroditis: a stem cellhypothesis of papillary carcinoma oncogenesis[J]. Hum Pathol, 2004, 35(4): 465-473.

[14] Takano T, Amino N. Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma[J]. Thyroid, 2005, 15(5): 432-438.

[15] 钱敏飞, 王家东. P63蛋白在甲状腺肿瘤中表达的意义[J]. 临床耳鼻喉头颈外科杂志, 2008, 22(19): 888-893.